Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up - Still a Buy?

Key Points

• Chugai Pharmaceutical's stock opened at $22.00, up from a previous close of $21.30, with the last traded price at $21.60.
• The company reported $2.01 billion in revenue and $0.20 earnings per share for the last quarter, forecasting 0.74 earnings per share for the current year.
• Chugai Pharmaceutical has a market capitalization of $70.97 billion and a price-to-earnings ratio of 27.30.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $21.30, but opened at $22.00. Chugai Pharmaceutical shares last traded at $21.60, with a volume of 9,892 shares traded.

Chugai Pharmaceutical Price Performance

The stock has a 50 day moving average price of $23.52 and a 200-day moving average price of $24.65. The stock has a market capitalization of $70.97 billion, a price-to-earnings ratio of 27.30 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%.The company had revenue of $2.01 billion for the quarter. As a group, research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.